TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Kalbe Farma performance stays strong, profit up 7.9% in H1
The pharmaceutical company saw revenue rise 6.6 percent yoy to Rp 12.37 trillion in the January-June period, supported by higher sales in its distribution services, prescription drug and consumer health product segments. The nutritional segment booked a decline.
Change text size
Gift Premium Articles
to Anyone
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
PT Kalbe Farma held its annual capital expenditure at Rp 1 trillion, which is mainly to be used to expand production and distribution capacity. (Kontan/Daniel Prabowo)
P
ublicly listed pharmaceutical firm PT Kalbe Farma saw a 7.9 percent annual rise in net profit to Rp 1.49 trillion (US$103.10 million) in the first half of 2021 following higher income across nearly all of its business segments and lower selling costs.
Kalbe’s latest financial report shows that revenue rose 6.6 percent year-on-year (yoy) to Rp 12.37 trillion in the January-June period, supported by higher sales in its distribution services, prescription drug and consumer health products segments. Only the nutritional products segment, which is dominated by powdered milk for all ages, booked a sales decline.
“The company is adapting by launching healthcare products such as herbal [goods], supplements, vitamins and medicines, more affordable nutrition products and also testing diagnostic services related to COVID-19,” Kalbe wrote in a statement on Friday.
Kalbe attributed the higher sales to improving macroeconomic conditions in the first half, as indicated by the government’s expectation of full-year GDP growth of 3.1 to 3.3 percent, a turnaround from the 1.26 percent contraction booked in the same period last year.
The company’s production costs rose 9.7 percent yoy to Rp 6.97 trillion in the first half, but selling costs — the biggest contributor to operational costs — dipped 1.1 percent to Rp 2.71 trillion over the same time period.
“The company is also combining product portfolio management strategies, managing the effectiveness of sales and marketing activities, transforming the use of digital technology and monitoring other operating costs to maintain net profit levels,” Kalbe wrote.
Read also: Kalbe Farma sales underwhelm investors
